Trial Profile
Established drug given to new indication Ipratropium bromide by exertional laryngeal obstruction (EILO - Exercise Induced Laryngeal Obstruction)[Ipratropium bromide ved anstrengelsesutløst laryngeal obstruksjon (EILO - Exercise Induced Laryngeal Obstruction)]
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jan 2021
Price :
$35
*
At a glance
- Drugs Ipratropium bromide (Primary)
- Indications Laryngospasm
- Focus Therapeutic Use
- 28 Jan 2021 Status changed from recruiting to completed.
- 28 May 2016 Planned End Date changed from 4 May 2015 to 4 Feb 2016.
- 12 Feb 2015 New trial record